Continuous Glucose Monitors Significantly Improve Type 2 Diabetes Care

The study, conducted across 22 primary care practices, followed 283 adults over 26 weeks. Participants using the wearable sensors achieved a 0.9 percentage point greater reduction in A1c levels compared to those receiving standard care. This margin exceeds the threshold typically defined as clinically significant, offering a potential shift in how millions of Americans manage their condition.

Dr. Tamara Oser, the study's lead author and director of the Primary Care Diabetes Lab at the University of Colorado Anschutz, emphasizes that the technology allows patients to observe immediate physiological responses to diet and physical activity. By providing real-time data, the devices help bridge a long-standing gap in clinical evidence for non-insulin-dependent patients. Currently, national guidelines for this group rely on lower-level research compared to insulin-dependent care. The research team intends for these results to influence future treatment recommendations and expand insurance coverage, making the monitors more accessible to the estimated 20 million U.S. adults who could benefit from improved glycemic control.